Lanadelumab Brand Name– TAKHZYRO
What is Lanadelumab
Lanadelumab is a parenteral plasma kallikrein inhibitor, monoclonal antibody indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older.
Compared to other parenteral therapies for the prophylaxis of angioedema, lanadelumab offers the advantages of less frequent dosing and potentially better safety profile.
In a randomized, placebo-controlled trial (RCT), the mean reduction in HAE attack rate was significantly higher in patients treated with lanadelumab compared to placebo over 26 weeks. In a rollover, open-label extension trial, patients received a single dose of lanadelumab 300 mg at study entry and were followed until the first HAE attack occurred.
At week 4, approximately 80% of patients who had been in the lanadelumab 300 mg subcutaneously every 2 weeks treatment group in the RCT remained attack free.
Indications
- angioedema prophylaxis
For angioedema prophylaxis in patients with hereditary angioedema (HAE)
Side Effects
- antibody formation
- diarrhea
- dizziness
- edema
- elevated hepatic enzymes
- erythema
- headache
- hematoma
- infection
- injection site reaction
- maculopapular rash
- myalgia
- paresthesias
- pruritus
- rash
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- breast-feeding
- laboratory test interference
- pregnancy
Interactions
There are no drug interactions associated with Lanadelumab products.
